The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.

Full article body is being fetched in the background. Refresh in a moment to see the complete paragraphs. For now this page shows a summary and AI analysis.